{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-23-000022","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.611983+00:00","generated_at":"2026-06-15T22:41:35.187115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immuneering Q1 net loss $13.6M; positive Phase 1 data for IMM-1-104 accelerates timeline","bullets":["Net loss $13.6M ($0.51/sh) for Q1 2023; cash & equivalents $91.5M as of Mar 31, 2023.","Positive initial Phase 1 PK, PD, safety data for IMM-1-104: significant PK Cmax, ~2h half-life, no DLTs.","RP2D expected early 2024 (accelerated); potential to assess preliminary efficacy sooner than anticipated.","Completed $30M stock offering (2.73M shares at $11.00); cash runway extended into 2025.","Appointed Harold E. Brakewood as CBO in March 2023; IND for IMM-6-415 expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-23-000022","json":"https://secwatch.observer/filing/0001790340-23-000022.json","markdown":"https://secwatch.observer/filing/0001790340-23-000022.md","text":"https://secwatch.observer/filing/0001790340-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/0001790340-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/imrx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:41:35.187115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13165398280e30e344a12305c480bb70eca38aa1","claim":"Immuneering Corp reported the first quarter ended March 31, 2023 results: net income $13.6 million, EPS $0.51 per share.","evidence_excerpt":"Net loss attributable to common stockholders was $13.6 million, or $0.51 per share, for the first quarter ended March 31, 2023, compared to $12.9 million, or $0.49 per share, for the first quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034023000022/0001790340-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$13.6 million"},{"label":"EPS","value":"$0.51 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}